Tradestie Institutional Equity Comparison Engine
TMCI vs MXCT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TMCI Overall Edge
TMCI Captures Institutional Edge (3โ0 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Treace Medical Concepts, Inc. Common Stock (TMCI) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, TMCI trades at N/M Forward P/E with -24.4% operating margin (-3.9% YoY revenue) versus MXCT at N/M Forward P/E and -85.5% operating margin (+48.7% YoY). In options structure, TMCI sits in CONSOLIDATION (100th %ile IV; Dealer Gamma Walls on Pro) against MXCT sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
TMCI N/M vs MXCT N/M Fwd P/E
Growth & Margin Winner
TMCI
Op Margin -24.4% vs -85.5% ยท YoY -3.9% vs +48.7%
Momentum & Technical Winner
TMCI
1Y +58.5% vs -19.4% ยท 52W Pos 74% vs 63%
Options & Structure Winner
TMCI
CONSOLIDATION (100th %ile IV) vs UNCLASSIFIED (N/A IV)
TMCI
NASDAQ
Treace Medical Concepts, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$4.31
-0.92% 1D
Market Cap
$285.2M
1M Return
+0.7%
1Y Return
+58.46%
Forward P/E
N/M
Unified AI Score
42.7 / 100
HOLD
Tech 25.0
Fund 45.0
Flow 67.0
Mom 50.0
MXCT
NASDAQ
MaxCyte, Inc. Common Stock
Services-Commercial Physical & Biological Research
$1.37
+7.03% 1D
Market Cap
$132.2M
1M Return
-4.2%
1Y Return
-19.41%
Forward P/E
N/M
Unified AI Score
41.7 / 100
SELL
Tech 46.0
Fund 52.0
Flow 62.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
TMCI +58.46%
MXCT -19.41%
Spread: +77.87 pp (TMCI Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | TMCI Revenue | MXCT Revenue | TMCI Op. Margin | MXCT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $40M | $10M | -9.0% | -93.7% | TMCI |
| FY2020 | $60M | $20M | 1.5% | -71.6% | TMCI |
| FY2021 | $90M | $20M | -17.5% | -84.3% | TMCI |
| FY2022 | $140M | $30M | -24.6% | -95.2% | TMCI |
| FY2023 | $190M | $20M | -27.5% | -247.7% | TMCI |
| FY2024 | $210M | $20M | -26.6% | -230.5% | TMCI |
| FY2025 | $210M | $20M | -25.5% | -247.6% | TMCI |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TMCI | MXCT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $285.2M | $132.2M | Larger Scale | TMCI |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -3.9% | +48.7% | Higher Growth | MXCT |
| Operating Margin (TTM) Profitability | -24.4% | -85.5% | Higher Margin | TMCI |
| Net Profit Margin Profitability | -27.4% | -81.4% | Higher Margin | TMCI |
| Return on Equity (ROE) Capital Efficiency | -74.0% | -16.9% | Higher ROE | MXCT |
| 52-Week Range Position Momentum | 74% ($1โ$5) | 63% ($1โ$2) | Stronger Trend | TMCI |
| Beta / 30D Volatility Risk Regime | 2.03ฮฒ ยท 110% Vol | 1.19ฮฒ ยท 96% Vol | Lower Realized Risk | MXCT |
| Unified Institutional Score Composite Signal | 42.7 / 100 (HOLD) | 41.7 / 100 (SELL) | Higher Composite | TMCI |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full TMCI vs MXCT Buy Guide
TMCI
CONSOLIDATION
106d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
MXCT
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither TMCI nor MXCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.